A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-XNW4107 in Comparison with Imipenem/Cilastatin/Relebactam in Adults with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
This study is a research project for adults who have a serious lung infection called pneumonia, which they caught while in hospital or while on a breathing machine. These infections are often caused by specific types of bacteria. The study aims to compare a new experimental medicine, called XNW4107, with a treatment that doctors already use, called Recarbrio. Both medicines are given directly into a vein. Researchers want to find out which treatment is better at helping patients survive and recover from these serious infections. They will be looking closely at how many people are alive after 14 days, and also checking other things like overall recovery and how well the treatment fights the bacteria. This is a crucial step in developing new and more effective ways to treat severe hospital-acquired infections.
At a glance
What is this study about?
This research study is for adults who have developed a serious lung infection, specifically pneumonia, while they are staying in hospital. This type of infection can be particularly challenging to treat, especially if you are also using a breathing machine (ventilator).
The main goal of this study is to test a new medicine, called XNW4107, and compare it with a treatment that is already available and used by doctors, called Recarbrio. Both of these medicines contain powerful antibiotics. We want to see if XNW4107 is as good as, or even better than, Recarbrio at fighting these infections and helping people get better. The medicines will be given directly into your bloodstream, usually through a drip.
To make sure the results are fair and accurate, this study is 'double-blind.' This means that neither you nor your doctor will know whether you are receiving XNW4107 or Recarbrio. This helps prevent any bias when we look at how well the treatments work. By comparing these two treatments, we hope to find safer and more effective ways to help patients recover from these serious hospital-acquired infections.
Key takeaways
- This study evaluates new treatments for severe lung infections caught in hospital.
- It compares a new experimental antibiotic, XNW4107, with an existing one, Recarbrio.
- Both medicines are given directly into a vein.
- The study is 'double-blind,' meaning you won't know which drug you receive.
- The main goal is to find out which treatment helps patients survive and recover best.
Who may be eligible?
This study is looking for adult patients who are currently in hospital and have been diagnosed with a specific type of lung infection called pneumonia. This includes pneumonia caught in hospital (hospital-acquired bacterial pneumonia) or if you are on a breathing machine (ventilator-associated bacterial pneumonia).
To join, you must be at least 18 years old. The medical team will check other specific health details to make sure this study is safe and appropriate for you. They will need to confirm that your infection is likely caused by a certain type of bacteria before you can take part.
There might be certain health conditions or medicines you are taking that would mean you couldn't join the study, as this helps keep everyone safe. Your doctor or the study team will go through all of these details with you carefully.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have pneumonia that you caught while in hospital?
- Is your pneumonia caused by certain types of bacteria?
- Are you currently in hospital receiving care for this infection?
- Have you discussed this study with your hospital doctor?
What does participation involve?
If you decide to take part in this study, you will receive one of the two study medicines directly into your vein. Doctors call this 'intravenous' treatment. The study team will closely monitor you throughout your hospital stay to see how the medicine is working and if you have any side effects.
This will involve regular check-ups, blood tests, and assessments of your overall health and lung infection. The team will be looking to see if your symptoms improve and if the bacteria causing the infection are being cleared. After you finish the treatment, there will be follow-up visits, which might involve telephone calls or short clinic visits, to check on your recovery over several weeks. The exact number and timing of these checks will be explained in detail by the study team.
Potential risks and benefits
Locations (2)
- —UnverifiedFrance
- —UnverifiedSpain
Common questions
What is hospital-acquired pneumonia?
It's a serious lung infection you can get while staying in hospital, often because you are already unwell or have had surgery.
What does 'ventilator-associated' mean?
This refers to pneumonia that develops in patients who are on a breathing machine (ventilator) to help them breathe.
What does 'double-blind' mean in this study?
It means neither you nor your doctor will know if you're getting the new medicine or the standard one. This helps make the study fair.
How will the medicine be given?
The medicine will be given directly into your vein, usually through a drip, just like many other hospital treatments.
Can I stop participating if I want to?
Yes, you can choose to leave the study at any time, for any reason, and your medical care will not be affected.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.